Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Bullish +55

Boston Scientific CEO pay rises again along with median employee pay

AI-generated analysis

๐Ÿข Boston Scientific reported $20.1 billion in revenue for 2025, representing a 20% year-over-year increase.

๐Ÿ’ฐ CEO Mike Mahoney's total compensation exceeded $23.5 million in 2025, surpassing the $20 million mark for the first time since 2009.

๐Ÿ“ˆ Mahoney's pay represents more than a $2 million increase from the previous year, driven by stock and option awards.

โœˆ๏ธ The CEO received $225,000 in annual corporate aircraft personal use value, an increase of $75,000 due to security considerations.

๐Ÿ‘ฅ Median employee pay at Boston Scientific also increased by double digits during the 2025 fiscal year.

๐Ÿ’ผ Executive Vice President Joe Fitzgerald earned $8 million total compensation, a 27% rise from the prior year.

๐Ÿ‘ค EVP Art Butcher received $6.5 million in total pay, with his overall compensation rising over 30% year-over-year.

๐Ÿšถ Daniel Brennan retired after 30 years at the company, receiving $6.3 million in final compensation before his departure.

๐Ÿ’ผ New CFO Jon Monson joined the leadership team and received $6.1 million in total compensation for 2025.

๐Ÿšด EVP Jeff Mirviss retired at the end of 2025 with a total compensation package of $4.2 million, a 3% increase from the previous year.

โš–๏ธ The Compensation Committee approved Mahoney's aircraft allocation increase after reviewing evolving security and travel requirements for senior executives.

๐Ÿš€ CEO Mahoney emphasized that the company remains focused on strengthening its innovation ecosystem and differentiated product pipeline.

Bullish Signals
  • Revenue grew 20% year-over-year to $20.1 billion in 2025, marking strong financial performance.
  • CEO Mike Mahoney's total compensation exceeded $23.5 million, surpassing the $20 million mark for the first time since 2009, reflecting the company's high value proposition for leadership.
  • Median employee pay rose by double digits in 2025, indicating significant investment in talent and competitive compensation standards.
  • Management continues to focus on strengthening its innovation ecosystem with a differentiated product pipeline designed for sustainable long-term growth.
  • CFO Jon Monson replaced outgoing CFO Daniel Brennan after over 30 years, ensuring continuity of leadership in financial operations.
  • Executive turnover at the highest levels appears orderly, with former leaders retiring smoothly and new executives like Jon Monson ready to step into key roles.
Risk Factors
  • CEO Mike Mahoney's annual compensation exceeded $23.5 million in 2025, representing an increase of over $2 million and breaking the $20 million barrier for the first time since Ray Elliott received $33.5 million in 2009.
  • Median employee pay also rose by double digits in 2025, widening the compensation gap between executives and regular staff despite claims of 'relentless innovation'.
  • The company approved a significant increase in personal use of corporate aircraft for CEO Mike Mahoney to $225,000 per year, up from $150,000, raising questions about executive perks versus shareholder value.
  • CVP and MedSurg President Art Butcher's total compensation rose by more than 30% year-over-year, while EVP and CFO Jon Monson received a higher base salary adjustment compared to his predecessor Daniel Brennan who retired with $6.7 million pay.
  • Former Peripheral Interventions President Jeff Mirviss retired at the end of 2025 after receiving $4.2 million in total compensation, suggesting high turnover or restructuring costs within specific business units.
  • The article notes that while revenue grew 20%, the focus on executive and median pay raises does not directly correlate to improved operational efficiency or profitability metrics.
Full Analysis
Boston Scientific CEO Mike Mahoney saw his total annual compensation rise to $23.5 million in 2025, marking an increase of over $2 million from the previous year and continuing a trend that has pushed executive pay above the $20 million threshold for the first time since 2009. The Massachusetts-based medical device manufacturer also reported robust financial performance for the period, with revenue reaching $20.1 billion in 2025, representing a 20% increase year-over-year. Alongside rising executive pay, the company disclosed that median employee compensation grew by double digits during the same timeframe, which Mahoney attributed to the companyโ€™s focus on relentless innovation and consistent financial growth aimed at sustaining long-term leadership in the medtech sector. Mahoneyโ€™s specific 2025 compensation package was detailed as consisting of a $1.44 million salary, $13.6 million in stock awards, $3.8 million in option awards, and a $4 million cash bonus. Additional benefits included a change in pension value of $441,611, other compensation totaling $287,799 (covering 401(k) matches and insurance), and personal use of the corporate aircraft valued at up to $225,000 for the year, an increase of $75,000 from 2024. This package represented a 10% rise over his prior yearโ€™s compensation. The company justified part of the aircraft cost increase by citing evolving security and travel considerations for senior executives approved by the Compensation Committee. Key executive officers also received substantial raises that reflected broader shifts in leadership and organizational structure. EVP and Cardiovascular Group President Joe Fitzgerald saw his total pay jump 27% to $8 million, while EVP and MedSurg and Asia Pacific Group President Art Butcher experienced a compensation increase of more than 30%, totaling $6.5 million. In finance leadership, former CFO Daniel Brennan retired in June 2025 after over 30 years with the company, having earned $6.3 million in his final year, while his successor Jon Monson received $6.1 million for the same period. Other executives including former EVP Jeff Mirviss and SVP Vance Brown also reported compensation figures ranging from $3.9 million to $4.2 million, with several retiring or transitioning roles at the end of 2025.